Jason Paris

Jason Paris, PhD Chief Scientific Officer

About

Jason Paris, PhD joined Arkana Laboratories in 2022. He received his BS from Marywood University in Scranton, PA and his PhD in Behavioral Neuroscience from The University at Albany-SUNY in Albany, NY. He completed postdoctoral fellowships in Pharmacology and Neurovirology at the Torrey Pines Institute for Molecular Studies and Virginia Commonwealth University. After completing his training, Dr. Paris established a pharmacology and neurovirology laboratory at the University of Mississippi that was continually funded by the National Institutes of Health. While at the University of Mississippi, he directed a contract research organization and established a Bioenergetics Phenotyping Core. Since joining Arkana, Dr. Jason Paris serves as the Chief Scientific Officer.

Education & Stats

Download CV
Joined the Arkana Team 2022
Doctor Of Philosophy University at Albany-SUNY
Postdoctoral Fellow Virginia Commonwealth University
Postdoctoral Fellow Torrey Pines Institute for Molecular Studies
Bachelors Of Psychology Marywood University

Featured Publications by Jason Paris, Ph.D.

HIV-1 Tat Disrupts Blood-Brain Barrier Integrity And Increases Phagocytic… HIV-1 Tat Disrupts Blood-Brain Barrier Integrity…

By Leibrand CR, Paris JJ, Ghandour MS, Knapp PE, Kim WK, Hauser KF, McRae M

January 2017

HIV-1 infection results in blood-brain barrier (BBB) disruption, which acts as a rate-limiting step for HIV-1 entry…

HIV-1 infection results in blood-brain barrier (BBB) disruption, which acts as a rate-limiting step for HIV-1 entry into the CNS and for subsequent neuroinflammatory/neurotoxic actions.

Effects of HIV-1 Tat expression on the penetration of horseradish peroxidase
Read on PubMed

Ionic Liquid Coating-Driven Nanoparticle Delivery to the Brain: Applications for… Ionic Liquid Coating-Driven Nanoparticle Delivery…

By Paris JJ

August 2025

Delivering cargo to the central nervous system (CNS) remains a pharmacological challenge. For infectious diseases such…

Delivering cargo to the central nervous system (CNS) remains a pharmacological challenge. For infectious diseases such as HIV, the CNS acts as a latent reservoir that is inadequately managed by systemic antiretrovirals (ARTs). ARTs thus cannot…

Read on PubMed

HIV-1 Tat Impairment of Mitochondrial Respiration via Complexes I and II Can Be… HIV-1 Tat Impairment of Mitochondrial Respiration…

By Paris JJ

August 2025

HIV-associated neurocognitive disorders are prevalent despite antiretroviral intervention. Some HIV virotoxins, such as…

HIV-associated neurocognitive disorders are prevalent despite antiretroviral intervention. Some HIV virotoxins, such as the trans-activator of transcription (Tat), are not targeted by antiretrovirals, and their neurotoxic actions may be exacerbated…

Read on PubMed

Age-Related Neuroendocrine, Cognitive, And Behavioral Co-Morbidities Are Promoted… Age-Related Neuroendocrine, Cognitive, And…

By Qrareya AN, Mahdi F, Kaufman MJ, Ashpole NM, Paris JJ

October 2022

In the U.S. about half of the HIV-infected individuals are aged 50 and older. In men living with HIV, secondary…

In the U.S. about half of the HIV-infected individuals are aged 50 and older. In men living with HIV, secondary hypogonadism is common and occurs earlier than in seronegative men, and its prevalence increases with age.

Read on PubMed

HIV-1 Tat Upregulates The Receptor For Advanced Glycation End Products And… HIV-1 Tat Upregulates The Receptor For Advanced…

By Qrareya AN, Wise NS, Hodges ER, Mahdi F, Stewart JA, Paris JJ

October 2022

Cardiovascular disorder (CVD) is a common comorbidity in people living with HIV (PLWH). Although the underlying…

Cardiovascular disorder (CVD) is a common comorbidity in people living with HIV (PLWH). Although the underlying mechanisms are unknown, virotoxic HIV proteins, such as the trans-activator of transcription (Tat), likely contribute to CVD pathogenesis.

HIV-1 Tat Upregulates The Receptor For Advanced Glycation End Products And Superoxide Dismutase-2
Read on MDPI

Independent Actions By Hiv-1 Tat And Morphine To Increase Recruitment Of… Independent Actions By Hiv-1 Tat And Morphine To…

By Leibrand CR, Paris JJ, Jones AM, Ohene-Nyakoc M, Rademeyera KM, Nass SR, Kim WK, Knapp PE, Hauser KF, McRae M

September 2022

Despite advances in the treatment of human immunodeficiency virus (HIV), approximately one-half of people infected with…

Despite advances in the treatment of human immunodeficiency virus (HIV), approximately one-half of people infected with HIV (PWH) experience neurocognitive impairment.

injected dextrans into iba-1-immunoreactive macrophages and microglia
Read on PubMed

Doctor Directory

Josephine Ambruzs, MD, MPH

Nephropathologist

Alejandro Best, MD

Nephropathologist, Assistant Physician Chief

Vanesa Bijol, MD

Nephropathologist

Christie Boils, MD

Nephropathologist

Stephen Bonsib, MD, MS

Emeritus Nephropathologist

T. David Bourne, MD

Neuropathologist, Nephropathologist

Clarissa Cassol, MD

Nephropathologist

Tiffany Caza, MD, PhD

Nephropathologist, Scientist

River Charles, MD

Nephropathologist

L. Nicholas Cossey, MD

Physician Director, Nephropathologist

Rachelle Gietzen, MD

Nephropathologist

Eric Goold, MD

Neuropathologist, Molecular Pathologist

Samar Hassen, PhD

Research Scientist

Randy Haun, PhD

Senior Scientist

Danni Holanda, MD

Nephropathologist

Chris Larsen, MD

Executive Director, Nephropathologist

Alan Lim, MD

Nephropathologist

Rebecca May, MD, PhD

Nephropathologist

Paul Miller, MD

Nephropathologist, Fellowship Program Director

Odia Molen, MD

Nephropathologist

Joel Murphy, MD

Nephropathologist, Visiting Scholars Program Director

Mohammad Obeidat, MD

Nephropathologist

Jason Paris, PhD

Chief Scientific Officer

Miran Rhee-Anagnost, MD

Nephropathologist

Shree Sharma, MD

Laboratory Director, Nephropathologist

Fred Silva, MD

Emeritus Nephropathologist

Jaime Singh, MD

Nephropathologist

Joshua Sonnen, MD

Neuropathologist

Cherry Starling, MD

Nephropathologist

Aaron Storey, PhD

Director of Mass Spectrometry Laboratory

Patrick D. Walker, MD

Founder, Nephropathologist

Jon Wilson, MD

Neuropathologist, Molecular Pathologist

Jason Paris, PhD

Chief Scientific Officer

Josephine Ambruzs, MD, MPH

Nephropathologist

Alejandro Best, MD

Nephropathologist, Assistant Physician Chief

Vanesa Bijol, MD

Nephropathologist

Christie Boils, MD

Nephropathologist

Stephen Bonsib, MD, MS

Emeritus Nephropathologist

T. David Bourne, MD

Neuropathologist, Nephropathologist

Clarissa Cassol, MD

Nephropathologist

Tiffany Caza, MD, PhD

Nephropathologist, Scientist

River Charles, MD

Nephropathologist

L. Nicholas Cossey, MD

Physician Director, Nephropathologist

Rachelle Gietzen, MD

Nephropathologist

Danni Holanda, MD

Nephropathologist

Chris Larsen, MD

Executive Director, Nephropathologist

Alan Lim, MD

Nephropathologist

Rebecca May, MD, PhD

Nephropathologist

Paul Miller, MD

Nephropathologist, Fellowship Program Director

Odia Molen, MD

Nephropathologist

Joel Murphy, MD

Nephropathologist, Visiting Scholars Program Director

Mohammad Obeidat, MD

Nephropathologist

Miran Rhee-Anagnost, MD

Nephropathologist

Shree Sharma, MD

Laboratory Director, Nephropathologist

Fred Silva, MD

Emeritus Nephropathologist

Jaime Singh, MD

Nephropathologist

Cherry Starling, MD

Nephropathologist

Patrick D. Walker, MD

Founder, Nephropathologist

T. David Bourne, MD

Neuropathologist, Nephropathologist

Eric Goold, MD

Neuropathologist, Molecular Pathologist

Joshua Sonnen, MD

Neuropathologist

Jon Wilson, MD

Neuropathologist, Molecular Pathologist

Josephine Ambruzs, MD, MPH

Nephropathologist

Clarissa Cassol, MD

Nephropathologist

Tiffany Caza, MD, PhD

Nephropathologist, Scientist

Samar Hassen, PhD

Research Scientist

Randy Haun, PhD

Senior Scientist

Rebecca May, MD, PhD

Nephropathologist

Jason Paris, PhD

Chief Scientific Officer

Joshua Sonnen, MD

Neuropathologist

Aaron Storey, PhD

Director of Mass Spectrometry Laboratory

Meet All Doctors and Team